Genpharmasec Targets Clinigenome India Exit by March 2027

Genpharmasec Limited has approved the sale of its entire stake in Clinigenome India Private Limited, targeting completion by March 31, 2027, after the subsidiary contributed Rs 100.47 lakh, or 0.72%, of consolidated turnover in the last financial year. No sale agreement or consideration has yet been finalised.

Genpharmasec announced the board decision on November 3, 2026, with its unaudited results for the quarter and half year ended September 30, 2026. The company described Clinigenome India as a non-material wholly owned subsidiary, which will cease to be a subsidiary once the proposed disposal is completed.

Why is Genpharmasec selling Clinigenome India?

Genpharmasec is selling Clinigenome India following board approval on November 3, 2026, but the filing gives no operational rationale, restructuring objective or intended use of proceeds. It identifies the company as non-material and says the proposal covers Genpharmasec’s entire equity stake.

Clinigenome India reported turnover of Rs 100.47 lakh in the last financial year, equal to 0.72% of Genpharmasec’s consolidated turnover. The subsidiary’s disclosed net worth was negative Rs 1.5441 crore; the annexure also showed a 2.35% figure alongside net worth, although the filing does not explain the calculation basis for that percentage.

Genpharmasec’s standalone accounts for the half year ended September 30, 2026 classify its investment in Clinigenome India as a non-current asset held for sale under Indian Accounting Standard 105, or Ind AS 105. The investment was carried at cost under Ind AS 27 and measured at the lower of carrying amount and fair value less costs to sell, with no impairment recognised for the six-month period.

Who is the proposed buyer and what price is agreed?

Micro Genomics India Private Limited is the proposed buyer, but Genpharmasec has not agreed or disclosed a transaction price as of November 3, 2026. The board said consideration would be negotiated and then determined and approved by directors.

The proposed buyer does not belong to Genpharmasec’s promoter or promoter group, according to the November 3 disclosure. The filing marks related-party-transaction treatment as not applicable and provides no information on Micro Genomics India’s ownership, operations, payment terms, valuation or funding.

The sale agreement was “yet to be entered” when the board made its disclosure on November 3, 2026. Genpharmasec said it would inform the exchanges on signing, meaning the named buyer does not yet establish a binding sale arrangement in the information disclosed.

Genpharmasec reported Rs 2.0023 crore of assets held for sale on its standalone balance sheet at September 30, 2026, against no such balance at March 31, 2026. That accounting balance is not identified as the consideration for Clinigenome India and should not be read as an agreed cash inflow.

When is the Clinigenome India sale expected to close?

Genpharmasec expects the proposed sale to close on or before March 31, 2027, unless its board determines and approves a different date. The deadline was disclosed on November 3, 2026, alongside confirmation that the agreement had not been signed.

The notes to the standalone financial results for the half year ended September 30, 2026 say the sale is expected to be completed within 12 months of classification as held for sale. Neither the board announcement nor the accounts specify regulatory approvals, conditions precedent, buyer financing or other closing requirements.

The November 3 filing also says the proposed transaction is not presented as a related-party transaction, a disposal outside a scheme of arrangement or a slump sale. Therefore, the announcement does not include a slump-sale value or scheme-compliance details under Regulation 37A of the Listing Obligations and Disclosure Requirements regulations.

How large is Clinigenome India compared with Genpharmasec’s business?

Clinigenome India’s Rs 100.47 lakh turnover in the last financial year was small beside Genpharmasec’s standalone revenue from operations of Rs 50.8308 crore in the quarter ended September 30, 2026. The parent company’s quarterly revenue increased from Rs 44.7844 crore in the June 2026 quarter and Rs 31.5637 crore in the September 2025 quarter.

For the half year ended September 30, 2026, Genpharmasec reported standalone revenue from operations of Rs 95.6152 crore, compared with Rs 43.6768 crore in the corresponding half of the previous year. The financial statements identify one business segment under Ind AS 108, so they do not provide a separate operating-segment result for Clinigenome India.

Standalone profit before tax rose to Rs 5.1555 crore for the half year ended September 30, 2026 from Rs 3.0865 crore a year earlier. These are parent-company figures, whereas Clinigenome India’s Rs 100.47 lakh turnover is presented as a share of consolidated turnover, so the disclosure does not quantify the disposal’s effect on consolidated profit.

Genpharmasec has not given a forecast for revenue, earnings, cash flow, borrowings or capital allocation following the proposed exit. The subsidiary’s negative Rs 1.5441 crore net worth, the absence of a settled consideration and the lack of current-period subsidiary earnings leave the financial outcome unresolved.

What other changes did Genpharmasec disclose on November 3?

Genpharmasec also disclosed the resignation of Hardik Makwana as company secretary and compliance officer, effective at the close of business on November 16, 2026. The stated reason was his pursuit of professional opportunities outside the organisation, and the filing does not link the resignation to the Clinigenome India transaction.

The board meeting on November 3, 2026 began at 4:30 p.m. and concluded at 5:15 p.m. In the same announcement, Genpharmasec approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, accompanied by limited review reports.

Conclusion

Genpharmasec has begun a planned full exit from Clinigenome India, a non-material subsidiary with Rs 100.47 lakh of turnover, or 0.72% of consolidated turnover, in the last financial year. The proposal identifies Micro Genomics India as buyer and sets a March 31, 2027 target, but its commercial terms remain open because no agreement or consideration has been disclosed.

The next item to watch is the sale agreement that Genpharmasec said it would report when signed. That disclosure should establish the negotiated consideration, payment and closing conditions, and whether the board retains the March 31, 2027 completion target or approves another date.